Amineptine

Amineptine

Amineptine is a type of antidepressant drug that belongs to the class of tricyclic antidepressants (TCA). It is unique in that it primarily affects the dopamine systems in the brain. It has been compared to other antidepressants such as imipramine, fluoxetine, amitriptyline, and sertraline in various studies.From: Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder [2019], Handbook of Chronic Depression [2019]

Psychotropic Use during Pregnancy

View Chapter

Purchase Book

Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022

“Bert” Bertis Britt Little

Data have been published for other non-tricyclic antidepressants that are not discussed earlier. No increased frequency of congenital anomalies was found among 40, 66, 48, and 23 infants exposed during the first trimester to amineptine, fluvoxamine, mianserin, and viloxazine, respectively (McElhatton et al., 1996; see Table 10.3).

Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder

View Article

Journal Information

Published in Expert Opinion on Pharmacotherapy, 2019

Mauro Giovanni Carta, Pasquale Paribello, Antonio Egidio Nardi, Antonio Preti

A 2009 Cochrane review on the efficacy of second-generation antipsychotics in depression and dysthymia management [76], endorses the use of low-dose amisulpride (i.e. around 50 mg/die) in dysthymia, as it presents an efficacy comparable to that of antidepressants. The most significant side effects reported include prolactin increase in studies comparing amisulpride to placebo, and weight gain in studies comparing the former to antidepressants. The studies included in the analysis compared amisulpride to different antidepressants including imipramine [77], fluoxetine [78], amitriptyline [79], amineptine [80], sertraline [81]. In a previously cited metanalysis [26], amisulpride appeared superior to fluoxetine and presented a lower drop rate as compared with imipramine. In a 2016 systematic review [70], Meister et al. confirmed the efficacy of amisulpride in PDD, and as previously reported found an increased risk for prolactin elevation, weight gain and loss of libido among the most common complaints.

Explore chapters and articles related to this topic

Psychotropic Use during Pregnancy

Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder